DAX23.931 -0,3%ESt505.356 -0,2%Top 10 Crypto13,89 -2,1%Dow42.222 -0,1%Nas19.223 +0,6%Bitcoin91.307 -1,9%Euro1,1430 +0,7%Öl64,84 +1,5%Gold3.378 +2,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 RENK RENK73 HENSOLDT HAG000 NVIDIA 918422 BioNTech (ADRs) A2PSR2 Tesla A1CX3T Siemens Energy ENER6Y BYD A0M4W9 Gerresheimer A0LD6E Lufthansa 823212 thyssenkrupp 750000 Bayer BAY001 BASF BASF11 Mercedes-Benz Group (ex Daimler) 710000 Deutsche Bank 514000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Zollchaos: DAX schließt tiefer -- US-Börsen uneinheitlich -- Trump will Stahlzölle verdoppeln -- DHL erhöht Preise für Privat-Pakete -- Tesla, Infineon, Rheinmetall, RENK, Siemens Energy im Fokus
Top News
So entwickeln sich Ölpreis, Goldpreis & Co. am Abend am Rohstoffmarkt So entwickeln sich Ölpreis, Goldpreis & Co. am Abend am Rohstoffmarkt
Mai-Rally bei Tesla-Aktie: Musk zurück, Probleme mit BYD, NIO & Co. bleiben Mai-Rally bei Tesla-Aktie: Musk zurück, Probleme mit BYD, NIO & Co. bleiben
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
FONDSPREMIERE: BIT Capital legt ersten Multi-Asset-Fonds auf

Theravance Biopharma Aktie

Handeln
Aktien-Sparplan anlegen
8,30 EUR +0,20 EUR +2,47 %
FSE
11,14 USD +1,96 USD +21,35 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.401,62 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1137V

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINKYG8807B1068

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolTBPH

Theravance Biopharma Aktien News

DatumMeistgelesen
PR NewswireTheravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress
Wer­bungTheravance Biopharma-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireTheravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireTheravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
PR NewswireTheravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
PR NewswireTheravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology
PR NewswireTheravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value
PR NewswireTheravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024
PR NewswireTheravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024
PR NewswireTheravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
PR NewswireTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients...
PR NewswireTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
PR NewswireTheravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
PR NewswireTheravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
PR NewswireTheravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference
PR NewswireTheravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System
PR NewswireTheravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference
PR NewswireViatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
PR NewswireViatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
PR NewswireTheravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
PR NewswireTheravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders
Wer­bung

Theravance Biopharma News

Theravance Biopharma News: auf dieser Seite finden Sie alle Theravance Biopharma News und Nachrichten zur Theravance Biopharma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Theravance Biopharma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Theravance Biopharma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.